The above unaudited financial results were reviewed by the Audit Committee and have been approved by the Board at its meeting held on October 30, 2009. The quarterly stand alone results are subject to Limited Review by Auditors of the Company.

The Consolidated financial results, which are optional, have been presented by the Company, so as to provide additional information.

The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement', AS-27 ' Financial Reporting of Interests in Joint Ventures' and includes financial results of all subsidiaries and Joint Ventures.

Investor complaints pending at the beginning of the quarter: Nil, received: 23, resolved: 23 and lying unresolved at the end of the quarter Nil.

Foreign Exchange (Gain)/Loss represents exchange differences arising on all foreign currency transactions. This includes Loss during the quarter due to restatement of Foreign Currency Convertible Bonds (net of Deposits) Rs.37 millions ( Rs.853 millions).

The Year ended March 31, .2009 unaudited results are subject to adjustment during the course of annual audit. The impact, if any, will be furnished in the audited results.

In respect of matters referred to in the limited review report by the Auditors for the quarter ended June 30, 2009 - (a) relating to non- provision of premium of Rs. 2732 millions on redemption of outstanding USD 192.80 Million Zero Coupon Foreign Currency Convertible Bonds (FCCBs), the management is of the opinion that the determination and crystallisation of liability is dependent upon the outcome of uncertain future events or actions, not wholly within the control of the Company and therefore the same has been considered as a "contingent liability" as at June 30, 2009. Further, the management continues to hold the same view as at September 30, 2009 on outstanding USD 192.80 Million FCCBs. (b) Gain for the quarter ended June 30, 2009 on buyback of FCCBs will be credited to "Reconstruction Reserve Account" on receipt of the approval for the Scheme of Arrangement from the Hon'ble High Court. This has no impact on the results of the Company for the quarter.

During the quarter, Trident Life Sciences Limited has become Wholly Owned Subsidiary of the Company by acquisition of shares. Further, the company has entered into an agreement with Mr.B.R.Sikri & Associates for establishing a 75:25 joint Venture for Injectable Products in the name of Auronext Pharma Pvt. Ltd. The said Company has since become a subisidiary of the Company.

Figures for the previous periods have been rearranged/regrouped wherever necessary.